Vaxcell-Bio Therapeutics Co. Ltd
Vaxcell-Bio Therapeutics Co., Ltd. develops and sells cancer immune cell therapy products in South Korea. The company was founded in 2010 and is headquartered in Hwasun-eup, South Korea.
Vaxcell-Bio Therapeutics Co. Ltd (323990) - Total Assets
Latest total assets as of September 2025: ₩70.50 Billion KRW
Based on the latest financial reports, Vaxcell-Bio Therapeutics Co. Ltd (323990) holds total assets worth ₩70.50 Billion KRW as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Vaxcell-Bio Therapeutics Co. Ltd - Total Assets Trend (2018–2024)
This chart illustrates how Vaxcell-Bio Therapeutics Co. Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Vaxcell-Bio Therapeutics Co. Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Vaxcell-Bio Therapeutics Co. Ltd's total assets of ₩70.50 Billion consist of 50.8% current assets and 49.2% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 10.2% |
| Accounts Receivable | ₩950.73 Million | 1.2% |
| Inventory | ₩237.79 Million | 0.3% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩2.34 Billion | 3.0% |
| Goodwill | ₩2.45 Billion | 3.2% |
Asset Composition Trend (2018–2024)
This chart illustrates how Vaxcell-Bio Therapeutics Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Vaxcell-Bio Therapeutics Co. Ltd's current assets represent 50.8% of total assets in 2024, a decrease from 94.2% in 2018.
- Cash Position: Cash and equivalents constituted 10.2% of total assets in 2024, up from 0.0% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, an increase from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 3.2% of total assets.
Vaxcell-Bio Therapeutics Co. Ltd Competitors by Total Assets
Key competitors of Vaxcell-Bio Therapeutics Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Vaxcell-Bio Therapeutics Co. Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Vaxcell-Bio Therapeutics Co. Ltd generates 0.02x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Vaxcell-Bio Therapeutics Co. Ltd is currently not profitable relative to its asset base.
Vaxcell-Bio Therapeutics Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.00 | 15.84 | 32.29 |
| Quick Ratio | 9.89 | 15.76 | 32.29 |
| Cash Ratio | 0.00 | 1.28 | 0.00 |
| Working Capital | ₩27.11 Billion | ₩ 41.16 Billion | ₩ 18.59 Billion |
Vaxcell-Bio Therapeutics Co. Ltd - Advanced Valuation Insights
This section examines the relationship between Vaxcell-Bio Therapeutics Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.33 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -9.5% |
| Total Assets | ₩76.94 Billion |
| Market Capitalization | $103.22 Million USD |
Valuation Analysis
Below Book Valuation: The market values Vaxcell-Bio Therapeutics Co. Ltd's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Vaxcell-Bio Therapeutics Co. Ltd's assets decreased by 9.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Vaxcell-Bio Therapeutics Co. Ltd (2018–2024)
The table below shows the annual total assets of Vaxcell-Bio Therapeutics Co. Ltd from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩76.94 Billion | -9.46% |
| 2023-12-31 | ₩84.98 Billion | +251.69% |
| 2022-12-31 | ₩24.16 Billion | -22.74% |
| 2021-12-31 | ₩31.28 Billion | -11.89% |
| 2020-12-31 | ₩35.50 Billion | +253.71% |
| 2019-12-31 | ₩10.04 Billion | -18.13% |
| 2018-12-31 | ₩12.26 Billion | -- |